Market reactionShares fell 16% on Nov 5.
Larimar Therapeutics is a clinical-stage company developing nomlabofusp, a frataxin replacement therapy for Friedreich's ataxia; it is not approved.
Larimar's case rests on nomlabofusp, an injected fusion protein that delivers frataxin, the protein missing in Friedreich's ataxia, with frataxin as a novel surrogate endpoint for accelerated approval. FDA said the existing data appear capable of supporting a BLA, and Larimar expects to complete it in the second half of 2026, targeting a mid-2027 launch if approved. Ten of 43 participants had anaphylaxis and left the study, and cash of $156.3 million should last into the third quarter of 2027.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Larimar completes the BLA and FDA accepts it for review
Does FDA accept the completed BLA for review on the frataxin surrogate?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Larimar plans to complete its rolling BLA for nomlabofusp in 2H 2026, seeking accelerated approval on skin frataxin, with a mid-2027 launch target
Accelerated approval bid for Friedreich's ataxia on a novel surrogate endpoint, with runway expiring near the decision and a 15% stock drop signaling market skepticism
FDA Grants Breakthrough Therapy Designation for Nomlabofusp in FA
7 anaphylaxis events in OL study; dosing regimen modified
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Nomlabofusp
Disease areas: Neuromuscular diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.